Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.

@article{Carr2003ImmunotherapyOA,
  title={Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.},
  author={Adriana Carr and Edmundo Denis Rodr{\'i}guez and Mar{\'i}a del Carmen Arango and Rolando Santana Camacho and Marta Cecilia Henao Osorio and Mariano R Gabri and Guido Carrillo and Zolidina Vald{\'e}s and Yan{\'i}n Bebelagua and Rolando Gual P{\'e}rez and Luis E. Fern{\'a}ndez},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 6},
  pages={
          1015-21
        }
}
PURPOSE A heterophilic ganglioside cancer vaccine was developed by combining NeuGcGM3 with the outer membrane protein complex of Neisseria meningitidis to form very small size proteoliposomes (VSSP). A phase I clinical trial was performed to determine safety and immunogenicity of this vaccine. PATIENTS AND METHODS Stage III to IV breast cancer patients received up to 15 (200 micro g) doses of the vaccine by intramuscular injection. The first five doses (induction phase) were given at 2-week… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

  • Human vaccines & immunotherapeutics
  • 2014
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.

  • Oral diseases
  • 2012
VIEW 3 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED